Rafael Holdings RFL
NYSE RFL
$2.29 -0.14 (-5.76%)
As of: Sep 9, 2026 · 3:59 PM EDT

Rafael Holdings (RFL) Non Operating Interest Expenses (2021 - 2026)

Rafael Holdings' (RFL) quarterly Non Operating Interest Expenses came in at $6000.0 in Q2 2026, down 96.36% year-over-year from $165000.0 in Q2 2025, and down 96.27% quarter-over-quarter from $161000.0 in Q1 2026.

Analysis

Rafael Holdings (RFL) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends

Rafael Holdings (RFL) has reported Non Operating Interest Expenses for 6 consecutive years, with $6000.0 the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Non Operating Interest Expenses fell 96.36% year-over-year to $6000.0 in Q2 2026; TTM through Apr 2026 was $495000.0, a 24.2% decrease from a year earlier, with the FY2025 full-year figure at $658000.0, up 165.32% from the prior year.
  • Non Operating Interest Expenses was $6000.0 for Q2 2026 at Rafael Holdings, down from $161000.0 in the prior quarter.
  • Over five years, Non Operating Interest Expenses peaked at $168000.0 in Q3 2025 and troughed at -$13000.0 in Q3 2022.
  • A 5-year average of $105857.1 and a median of $123500.0 in 2022 frame the typical range for Non Operating Interest Expenses.
  • Across the five-year window, Non Operating Interest Expenses tumbled 122.03% in 2022 and jumped 769.23% in 2023, its largest moves.
  • Over 5 years, Non Operating Interest Expenses stood at $87000.0 in 2022, then changed by 0.0% to $87000.0 in 2023, then surged by 86.21% to $162000.0 in 2024, then retreated by 1.23% to $160000.0 in 2025, then slumped by 96.25% to $6000.0 in 2026.
  • The last three Non Operating Interest Expenses figures came in at $6000.0 (Q2 2026), $161000.0 (Q1 2026), and $160000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Rafael Holdings 117.57 Mn 117.57 Mn 171,000.00 6,000.00
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 6,000.00
Jan 31, 2026 161,000.00
Oct 31, 2025 160,000.00
Jul 31, 2025 168,000.00
Apr 30, 2025 165,000.00
Jan 31, 2025 163,000.00
Oct 31, 2024 162,000.00
Jul 31, 2024 163,000.00
Apr 30, 2024 85,000.00
Jul 31, 2023 87,000.00
Oct 31, 2022 87,000.00
Jul 31, 2022 -13,000.00
Apr 30, 2022 1,000.00
Jan 31, 2022 87,000.00
Oct 31, 2021 271,000.00
Jul 31, 2021 59,000.00
Apr 30, 2021 3,000.00